A detailed history of Bank Of America Corp transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Bank Of America Corp holds 778,471 shares of OCUL stock, worth $6.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
778,471
Previous 1,036,171 24.87%
Holding current value
$6.63 Million
Previous $7.09 Million 4.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.45 - $9.23 $1.66 Million - $2.38 Million
-257,700 Reduced 24.87%
778,471 $6.77 Million
Q2 2024

Aug 14, 2024

BUY
$4.2 - $8.69 $3.4 Million - $7.03 Million
809,118 Added 356.36%
1,036,171 $7.09 Million
Q1 2024

May 15, 2024

BUY
$3.85 - $10.93 $539,246 - $1.53 Million
140,064 Added 161.01%
227,053 $2.07 Million
Q4 2023

Feb 14, 2024

SELL
$2.08 - $4.52 $16,879 - $36,679
-8,115 Reduced 8.53%
86,989 $387,000
Q2 2023

Aug 14, 2023

BUY
$4.6 - $7.64 $130,285 - $216,387
28,323 Added 42.41%
95,104 $490,000
Q1 2023

May 12, 2023

SELL
$2.79 - $6.27 $87,128 - $195,805
-31,229 Reduced 31.86%
66,781 $351,000
Q4 2022

Feb 10, 2023

BUY
$2.61 - $4.41 $104,334 - $176,289
39,975 Added 68.88%
98,010 $275,000
Q3 2022

Nov 14, 2022

BUY
$4.09 - $6.5 $76,581 - $121,706
18,724 Added 47.63%
58,035 $240,000
Q2 2022

Aug 12, 2022

SELL
$3.01 - $5.22 $30,882 - $53,557
-10,260 Reduced 20.7%
39,311 $158,000
Q1 2022

May 16, 2022

SELL
$4.83 - $7.35 $161,978 - $246,489
-33,536 Reduced 40.35%
49,571 $246,000
Q4 2021

Feb 08, 2022

BUY
$6.16 - $12.07 $187,652 - $367,688
30,463 Added 57.87%
83,107 $579,000
Q3 2021

Nov 15, 2021

BUY
$9.7 - $14.34 $161,078 - $238,130
16,606 Added 46.08%
52,644 $526,000
Q2 2021

Sep 13, 2021

BUY
$13.43 - $19.16 $483,990 - $690,488
36,038 New
36,038 $511,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $656M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.